FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593546409> ?p ?o ?g. }

• W2593546409 endingPage "729" @default.
• W2593546409 startingPage "723" @default.
• W2593546409 abstract "Abstract Hyponatremia is a common electrolyte disorder in cancer patients and has been associated with poor prognosis. A frequent cause of cancer‐related hyponatremia is the syndrome of inappropriate antidiuretic hormone ( SIADH ). This study was a post hoc subgroup analysis of the SALT ‐1 (Study of Ascending Levels of Tolvaptan in Hyponatremia) and SALT ‐2 clinical trials. Hyponatremic subjects with SIADH and cancer received the oral selective vasopressin V2‐receptor antagonist tolvaptan ( n = 12) or matching placebo ( n = 16) once‐daily for 30 days. The initial tolvaptan dose (15 mg) was titrated over 4 days to 30 or 60 mg per day, as needed, according to serum sodium level and tolerability. Baseline serum sodium levels in the SIADH /cancer cohort of the SALT trials was 130 and 128 mEq/L for tolvaptan and placebo, respectively. Mean change from baseline in average daily serum sodium AUC for tolvaptan relative to placebo was 5.0 versus −0.3 mEq/L ( P < 0.0001) at day 4, and 6.9 versus 1.0 mEq/L ( P < 0.0001) at day 30; the observed treatment effects were similar to those in the overall SIADH population (i.e., with and without cancer) at both time points. Serum sodium normalization was observed in 6/12 and 0/13 subjects at day 4 and 7/8 and 2/6 subjects at day 30 in the tolvaptan and placebo groups, respectively ( P < 0.05 for both). Common treatment‐emergent AE s for tolvaptan were consistent with previously reported results. In this post hoc study of the SALT trial population, oral tolvaptan was an effective and safe therapy for the treatment of hyponatremia in subjects with SIADH and cancer." @default.
• W2593546409 created "2017-03-16" @default.
• W2593546409 creator A5015329014 @default.
• W2593546409 creator A5016444110 @default.
• W2593546409 creator A5025078744 @default.
• W2593546409 creator A5048487071 @default.
• W2593546409 creator A5049217528 @default.
• W2593546409 creator A5051197194 @default.
• W2593546409 creator A5083652416 @default.
• W2593546409 date "2017-03-02" @default.
• W2593546409 modified "2023-10-01" @default.
• W2593546409 title "Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the <scp>SALT</scp> ‐1 and <scp>SALT</scp> ‐2 trials" @default.
• W2593546409 cites W1839859385 @default.
• W2593546409 cites W1919282616 @default.
• W2593546409 cites W1976053112 @default.
• W2593546409 cites W1999147615 @default.
• W2593546409 cites W2006792424 @default.
• W2593546409 cites W2034066102 @default.
• W2593546409 cites W2036793006 @default.
• W2593546409 cites W2051613372 @default.
• W2593546409 cites W2054348019 @default.
• W2593546409 cites W2060747558 @default.
• W2593546409 cites W2061328035 @default.
• W2593546409 cites W2106959366 @default.
• W2593546409 cites W2115109482 @default.
• W2593546409 cites W2120040647 @default.
• W2593546409 cites W2125131255 @default.
• W2593546409 cites W2129086934 @default.
• W2593546409 cites W2134397687 @default.
• W2593546409 cites W2134850869 @default.
• W2593546409 cites W2164034075 @default.
• W2593546409 cites W2319039886 @default.
• W2593546409 doi "https://doi.org/10.1002/cam4.805" @default.
• W2593546409 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5387121" @default.
• W2593546409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28251822" @default.
• W2593546409 hasPublicationYear "2017" @default.
• W2593546409 type Work @default.
• W2593546409 sameAs 2593546409 @default.
• W2593546409 citedByCount "22" @default.
• W2593546409 countsByYear W25935464092017 @default.
• W2593546409 countsByYear W25935464092018 @default.
• W2593546409 countsByYear W25935464092019 @default.
• W2593546409 countsByYear W25935464092020 @default.
• W2593546409 countsByYear W25935464092021 @default.
• W2593546409 countsByYear W25935464092022 @default.
• W2593546409 countsByYear W25935464092023 @default.
• W2593546409 crossrefType "journal-article" @default.
• W2593546409 hasAuthorship W2593546409A5015329014 @default.
• W2593546409 hasAuthorship W2593546409A5016444110 @default.
• W2593546409 hasAuthorship W2593546409A5025078744 @default.
• W2593546409 hasAuthorship W2593546409A5048487071 @default.
• W2593546409 hasAuthorship W2593546409A5049217528 @default.
• W2593546409 hasAuthorship W2593546409A5051197194 @default.
• W2593546409 hasAuthorship W2593546409A5083652416 @default.
• W2593546409 hasBestOaLocation W25935464091 @default.
• W2593546409 hasConcept C126322002 @default.
• W2593546409 hasConcept C126894567 @default.
• W2593546409 hasConcept C134018914 @default.
• W2593546409 hasConcept C142724271 @default.
• W2593546409 hasConcept C197934379 @default.
• W2593546409 hasConcept C204787440 @default.
• W2593546409 hasConcept C27081682 @default.
• W2593546409 hasConcept C2776370428 @default.
• W2593546409 hasConcept C2776703092 @default.
• W2593546409 hasConcept C2778375690 @default.
• W2593546409 hasConcept C2779420931 @default.
• W2593546409 hasConcept C2780615674 @default.
• W2593546409 hasConcept C2908647359 @default.
• W2593546409 hasConcept C67761136 @default.
• W2593546409 hasConcept C71924100 @default.
• W2593546409 hasConcept C90924648 @default.
• W2593546409 hasConcept C99454951 @default.
• W2593546409 hasConceptScore W2593546409C126322002 @default.
• W2593546409 hasConceptScore W2593546409C126894567 @default.
• W2593546409 hasConceptScore W2593546409C134018914 @default.
• W2593546409 hasConceptScore W2593546409C142724271 @default.
• W2593546409 hasConceptScore W2593546409C197934379 @default.
• W2593546409 hasConceptScore W2593546409C204787440 @default.
• W2593546409 hasConceptScore W2593546409C27081682 @default.
• W2593546409 hasConceptScore W2593546409C2776370428 @default.
• W2593546409 hasConceptScore W2593546409C2776703092 @default.
• W2593546409 hasConceptScore W2593546409C2778375690 @default.
• W2593546409 hasConceptScore W2593546409C2779420931 @default.
• W2593546409 hasConceptScore W2593546409C2780615674 @default.
• W2593546409 hasConceptScore W2593546409C2908647359 @default.
• W2593546409 hasConceptScore W2593546409C67761136 @default.
• W2593546409 hasConceptScore W2593546409C71924100 @default.
• W2593546409 hasConceptScore W2593546409C90924648 @default.
• W2593546409 hasConceptScore W2593546409C99454951 @default.
• W2593546409 hasFunder F4320307765 @default.
• W2593546409 hasFunder F4320307776 @default.
• W2593546409 hasFunder F4320310030 @default.
• W2593546409 hasFunder F4320312517 @default.
• W2593546409 hasIssue "4" @default.
• W2593546409 hasLocation W25935464091 @default.
• W2593546409 hasLocation W25935464092 @default.
• W2593546409 hasLocation W25935464093 @default.
• W2593546409 hasOpenAccess W2593546409 @default.

• next